Kalbe Farma Tbk PT
IDX:KLBF
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| ID |
|
Kalbe Farma Tbk PT
IDX:KLBF
|
49.6T IDR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
990.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD |
Loading...
|
Market Distribution
| Min | -87 446.9% |
| 30th Percentile | 9.8% |
| Median | 20.5% |
| 70th Percentile | 37% |
| Max | 1 023 491.4% |
Other Profitability Ratios
Kalbe Farma Tbk PT
Glance View
Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Kalbe Farma Tbk PT is 39.5%, which is above its 3-year median of 38.3%.
Over the last 3 years, Kalbe Farma Tbk PT’s Gross Margin has decreased from 40.7% to 39.5%. During this period, it reached a low of 37.2% on Jun 30, 2024 and a high of 40.7% on Sep 30, 2022.